BioCryst is profitable. Now it wants to buy more rare disease drugs
分析失败
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
LISA · 延伸对话
与 Lisa 深入探讨这篇报告
基于本报告上下文的延伸分析
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
基于本报告上下文的延伸分析